Abstract
Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.
Original language | English (US) |
---|---|
Pages (from-to) | 55-59 |
Number of pages | 5 |
Journal | Seminars in Arthritis and Rheumatism |
Volume | 45 |
Issue number | 1 |
DOIs | |
State | Published - Aug 1 2015 |
Keywords
- Mycophenolate mofetil
- PCNSV
- Therapy
- Vasculitis
ASJC Scopus subject areas
- Rheumatology
- Anesthesiology and Pain Medicine